This paper is in the following e-collection/theme issue:

Digital Health Reviews (1297) Web-based and Mobile Health Interventions (3319) Digital Mental Health Interventions, e-Mental Health and Cyberpsychology (1532) Depression and Mood Disorders; Suicide Prevention (1371) Behavior Change (715) Reviews in Digital Mental Health (245)

Published on in Vol 25 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/41643, first published .
Internet-Based Behavioral Activation for Depression: Systematic Review and Meta-Analysis

Internet-Based Behavioral Activation for Depression: Systematic Review and Meta-Analysis

Internet-Based Behavioral Activation for Depression: Systematic Review and Meta-Analysis

Authors of this article:

Carolin Sophie Alber1 Author Orcid Image ;   Lena Violetta Krämer1 Author Orcid Image ;   Sophia Marie Rosar1 Author Orcid Image ;   Claudia Mueller-Weinitschke1 Author Orcid Image
Article Authors Cited by (10) Tweetations (3) Metrics

    Review

    Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology, University of Freiburg, Freiburg, Germany

    Corresponding Author:

    Claudia Mueller-Weinitschke, MSc

    Department of Rehabilitation Psychology and Psychotherapy

    Institute of Psychology

    University of Freiburg

    Engelbergerstraße 41

    Freiburg, 79085

    Germany

    Phone: 49 (0)761 203 9439

    Email: claudia.mueller-weinitschke@psychologie.uni-freiburg.de


    Background: Behavioral activation is an effective treatment for reducing depression. As depressive disorders affect many people worldwide, internet-based behavioral activation (iBA) could provide enhanced treatment access.

    Objective: This study aimed to investigate whether iBA is effective in reducing depressive symptoms and to assess the impact on secondary outcomes.

    Methods: We systematically searched MEDLINE, PsycINFO, PSYNDEX, and CENTRAL up to December 2021 for eligible randomized controlled trials. In addition, a reference search was conducted. Title and abstract screening, as well as a full-text screening, was conducted by 2 independent reviewers. Randomized controlled trials that investigated the effectiveness of iBA for depression as a treatment or main component were included. Randomized controlled trials had to report depressive symptoms, with a quantitative outcome measure and assess an adult population with depressive symptoms above cutoff. Two independent reviewers performed the data extraction and risk of bias assessment. Data were pooled in random-effects meta-analyses. The primary outcome was self-reported depressive symptoms posttreatment. This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines.

    Results: A total of 12 randomized controlled trials, with 3274 participants (88% female, 43.61 years) were included. iBA was more effective in reducing depressive symptom severity posttreatment than inactive control groups (standardized mean difference −0.49; 95% CI −0.63 to −0.34; P<.001). The overall level of heterogeneity was moderate to substantial (I2=53%). No significant effect of iBA on depressive symptoms could be found at 6-month follow-up. Participants assigned to iBA also experienced a significant reduction of anxiety and a significant increase in quality of life and activation compared to the inactive control groups. The results remained robust in multiple sensitivity analyses. The risk of bias assessment revealed at least some concerns for all studies, and there was evidence of slight publication bias.

    Conclusions: This systematic review and meta-analysis implies that iBA is effective in reducing depressive symptoms. It represents a promising treatment option, providing treatment access where no treatment is available yet.

    Trial Registration: International Prospective Register of Systematic Reviews CRD42021236822; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=236822

    J Med Internet Res 2023;25:e41643

    doi:10.2196/41643

    Keywords

    behavioral activation; depression; systematic review; meta-analysis; internet- and mobile-based intervention 


    Depression is a worldwide health problem reducing the quality of life and increasing the relative risk for mortality [1-3]. Still, an insufficient number of treatment options for depression exists, increasing the risk of chronification [4]. New treatment options, which can provide enhanced treatment access, are urgently needed [5].

    Behavioral activation (BA) is an effective treatment for reducing depressive symptoms [6]. Originally developed by Lewinsohn in 1974, the BA framework suggests that depression evolves due to low activity levels and an insufficient level of response-contingent reinforcement [7]. Behavioral treatment elements (eg, activity monitoring, activity scheduling, and values assessment) aim to increase a patient’s daily activities and access to positive reinforcement [8]. Various studies and meta-analyses show that BA is effective as a stand-alone treatment in reducing depression [9-11] and comparably effective to cognitive behavioral therapy (CBT) [9,12-14]. BA holds several advantages: It contains fewer treatment elements than CBT, making it parsimonious and easily comprehensible to patients [15,16]. It is simple to deliver and needs little training and experience from therapists [13,15]. BA can potentially reduce the need for costly professional training, increase access to psychological therapies, and reduce waiting times [6]. It might therefore be particularly suitable for implementation via the internet [17].

    There exist several studies implementing internet-based BA (iBA) interventions [18-22], and few reviews on iBA [17,23]. The option to conduct a comprehensive meta-analysis on iBA was previously limited due to the small number of primary studies on iBA. The previous reviews [17,23] had to be built on heterogeneous populations, delivery modes, and intervention rationales, resulting in high clinical heterogeneity. Despite these constraints, a meta-analysis showed promising results in favor of iBA (standardized mean difference [SMD] −0.67; 95% CI −0.96 to −0.37; P<.001) [17]. Yet, the high clinical heterogeneity made it difficult to draw valid conclusions on the effectiveness of iBA. Publication bias could not be assessed due to the limited number of included studies.

    In our meta-analysis, we want to provide a full picture of iBA effectiveness, including the most recent developments in iBA research. To address the methodological and practical limitations of the former meta-analysis [17] and especially reduce clinical heterogeneity, we specify and narrow the inclusion criteria by reducing the variety of eligible study populations and increasing the similarity of interventions regarding their content elements and delivery mode. The following main research questions are addressed: (1) is iBA effective in treating depressive symptoms compared to inactive control groups (CGs)? (2) How does iBA compare to other treatments concerning the effectiveness for the treatment of depressive symptoms? (3) Does iBA have an effect on secondary outcomes?


    Preregistration and Reporting

    This systematic review and meta-analysis was preregistered in the International Prospective Register of Systematic Reviews (CRD42021236822). The reporting follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [24] (see Multimedia Appendix 1). Amendments and specifications to the PROSPERO registration can be found in Multimedia Appendix 2.

    Search Strategy and Selection Criteria

    MEDLINE, PsycINFO, and PSYNDEX (via EBSCO), as well as CENTRAL, were searched for eligible records from database inception until December 13, 2021.

    Suitable for inclusion were the following: (1) randomized controlled trials (RCTs), (2) written in English or German, that (3) assessed an adult sample (aged 18 years or older) of depressed individuals (symptoms above predefined cutoff score on depression measures), that (4) evaluated the effectiveness of an internet-based intervention, with (5) BA as an exclusive treatment or main component, and (6) reported depressive symptom severity as a quantitative outcome measure. There were no restrictions on CGs, further sociodemographic characteristics of participants, or publication date. Studies containing videoconferencing or telephone-based therapy were excluded as they resemble face-to-face therapy.

    The search string (Multimedia Appendix 3) included a combination of terms concerning digital health, BA, depression, and RCTs. For each category, we derived search terms based on search terms of former meta-analyses [9,11,17,25] and theoretical considerations (CSA, CM-W, and LVK). Different from previous meta-analyses [9,17], the search term excluded near-operators and the umbrella term “behavior therapy,” as we classified these terms as too unspecific for the distinct field of BA. In the last step, this search string was adapted for each database’s requirements. The quality of the search string was evaluated using a predefined validation set including all relevant studies from previous meta-analyses (Multimedia Appendix 4) [9,17]. All studies of our validation set were detected. Reference lists of included studies were searched for additional eligible records.

    Title and abstract screening, as well as full-text screening, was fully conducted by 2 independent reviewers (CSA and CM-W). Reasons for the exclusion of studies were recorded throughout the process. Discrepancies were resolved in discussion with a third reviewer (LVK). The selection process was based on a prior developed inclusion criteria checklist (Multimedia Appendix 5).

    Data Extraction

    Data were extracted independently by 2 reviewers (CSA and SMR) using a previously established data extraction sheet. The following data were extracted: data describing the (1) publication of the study, (2) population, (3) interventions, (4) comparators, (5) study design, (6) outcomes, and (7) study characteristics (Multimedia Appendix 6).

    Data were extracted for the main outcome of depressive symptoms as well as anxiety, quality of life, and activation as secondary outcomes. If necessary data were not reported, we contacted the corresponding authors via email. All requested data were provided. If multiple measures were used, data extraction was prioritized as follows: (1) validated questionnaires, (2) clinical ratings, and (3) single-item analysis. Wherever possible, intention-to-treat (ITT) data were used. ITT data were defined as analysis based on assignment to the intervention, meaning all randomized participants were included in the analysis.

    Data Analysis

    We conducted a random-effects meta-analysis for the main outcome of depressive symptoms (main analysis) against inactive CGs at posttreatment. In addition to the main analysis on inactive CGs, we conducted random-effects meta-analyses for the outcome of depressive symptoms against active CGs (cognitive interventions and mindfulness). Subgroup and sensitivity analyses were performed for the main analysis (inactive CGs) only.

    Subgroup analyses were preplanned, investigating differences regarding (1) the mode of delivery of iBA via browser-based digital intervention or smartphone app and (2) the amount of guidance (unguided intervention/minimal guidance/guided intervention; for the classification see Multimedia Appendix 7) within iBA interventions.

    Sensitivity analyses served to evaluate the robustness of the effect retrieved from the main analysis. We repeated the main analysis but used (1) the alternative outcome measure for depressive symptoms if multiple instruments were used in the respective primary study. Additionally, we conducted sensitivity analyses with respective subsamples of studies that (2) investigated depressive symptoms, excluding postnatal depression, (3) reported ITT data, (4) did not include any additional module content other than BA, (5) reported depressive symptoms above this meta-analysis’ predefined cutoff, excluding studies which reported only mild depressive symptoms at baseline, (6) were of acceptable methodological quality, excluding interventions that were at high risk of bias and, (7) reported data for adult samples only, excluding the study that reported data for participants at the age of 16 years or older [18].

    We conducted a post hoc meta-analysis for the main outcome of depressive symptoms at the 6-month follow-up to investigate the stability of effects, as this was the longest follow-up time point for which results from more than 2 data sets were available. The effect of iBA on depressive symptoms at posttreatment was also assessed compared to cognitive interventions (CBT/cognitive therapy) and mindfulness, as more than 1 study included these CGs. Secondary outcome analyses were conducted comparing iBA against inactive CGs at posttreatment if more than 2 comparisons were available.

    Data analysis was performed using Review Manager (RevMan 5.4) [26] for Windows provided by the Cochrane Collaboration. We estimated SMDs using Hedges g and 95% CIs. Inverse variance was used to weight studies. Two-sided P<.05 indicated statistical significance. Statistical heterogeneity of studies was judged using I2 statistics and interpreted according to the GRADE handbook. An I2 score of less than 40% indicates low, 30%-60% moderate, 50%-90% substantial, and 75%-100% considerable heterogeneity [27]. Publication bias was assessed visually via a funnel plot for the primary outcome of depressive symptoms at posttreatment.

    Risk of Bias

    Two reviewers (CSA and SMR) independently rated the risk of bias of all included studies using the Cochrane Collaboration’s Risk of Bias tool (RoB 2 [28]). Disagreements were resolved by discussion with a third reviewer (CM-W).


    Study Selection

    We identified 2499 records for screening, of which 12 publications met inclusion criteria. As 1 publication included 2 separate studies, a total of 13 studies [18-22,29-35] could be included in this systematic review, and 12 studies could be included in the quantitative meta-analysis [18-22,29,30,32-35] with 3274 baseline participants (see flowchart in Figure 1).

    ‎
    Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart. BA: behavioral activation; RCT: randomized controlled trial.

    Study Characteristics

    Study characteristics for the included studies are provided in Table 1. Included studies were published between 2013 and 2021. All studies investigated adult samples. One study had an age cutoff of 16 years, but the sample consisted of 97.4% participants aged 18 years or older (mean 24.48, SD 5.07 years) [18]. The mean age of all included participants in the meta-analysis was 43.61 (SD 9.91) years. The proportion of female participants ranged from 67% to 100%. Two studies included exclusively women with postpartum depression [33,34]; all other studies investigated general depression. The majority of studies were conducted in Western Europe [19,21,30-34] and the United States [20,29,35]. One study each was conducted in Indonesia [18], Brazil, and Peru [22]. Most studies compared an iBA intervention with an inactive CG: either treatment as usual [18,20-22,29,33,34] or waitlist control group [19,30,32,35] as defined by the authors. Some studies had additional active CGs (CBT [20,29]; cognitive therapy [35]; and mindfulness [21]), and 1 study compared with an active CG only (mindfulness [31]) and was therefore not included in the main analysis. There was 1 study [32] that investigated 2 BA interventions based either on the BA model of Martell or Lewinsohn. As this study presented only 1 CG, we included only the BA intervention based on Martell model of BA to prevent repeating the standard error of this CG. iBA interventions in primary studies were either transmitted as browser-based digital interventions [18,19,21,30,32-34] or via smartphone app [20,22,29,31,35]. The length of iBA interventions ranged from 2 to 15 weeks, from 6 to 18 modules, and from 10 minutes to 1 hour for each module. Posttreatment assessment varied from 2 to 17 weeks after baseline, depending on intervention length. There were 3 unguided interventions [20,21,29] and 4 interventions providing minimal guidance [19,22,30], consisting of technical and administrative support or motivational reminders. The remaining 6 interventions were guided [18,31-35] and used limited therapist support via telephone or messaging service. While most studies implemented pure iBA interventions, there were 4 studies that included minimal additional modules: acceptance and mindfulness of thoughts [19], problem-solving [30], and rumination [33,34] (details on intervention description are displayed in Multimedia Appendix 8).

    All studies used validated questionnaires to measure depressive symptoms as well as the respective secondary outcomes if these were available (Table 1). An additional clinical rating for depression was used in 1 study [19]. A follow-up measure at 6 months after baseline was offered by 2 studies [18,22]. Of the 12 studies included in the main analysis, the reported data of 10 studies was based on assigned randomization [18,19,21,22,30,32-35], of which 6 studies provided estimations for missing data (eg, via multiple imputations) and were classified as ITT [18,19,31,32,34,35].

    Table 1. Study characteristics.
    SourceCountryPopulation (cutoff for inclusion)Baseline (female), n (%)Age at baseline (years), mean (SD)InterventionControl groupsMeasure time pointsOutcomes (measures)ITT-data availablea,bDropout rate at posttreatment (%)







    		Posttreatment in weeksFollow-up in months

    		IGcCGd
    Araya et al, 2021 [22]BrazilAdults with depressive symptoms (PHQ-9 ≥10),e hypertension and diabetes880 (86.48)56.02 (11.59)fSmartphone-based BAg app (CONEMO app)Enhanced usual care126Depressive symptoms (PHQ-9), quality of life (EQ-5D-3L),h activation (BADS-SF)iNo49 (11)41 (9)
    Araya et al, 2021 [22]PeruAdults with depressive symptoms (PHQ-9≥10), hypertension and diabetes432 (81.48)59.75 (11.22)fSmartphone-based BA app (CONEMO app)Enhanced usual care126Depressive symptoms (PHQ-9), quality of life (EQ-5D-3L), activation (BADS-SF)No12 (6)10 (5)
    Arjadi et al, 2018 [18]IndonesiaIndividuals with MDDj or PDDk diagnosis (PHQ-9≥10)313 (81)24.48 (5.07)Browser-based digital BA intervention (Guided Act and Feel Indonesia)TAUl103, 6Depressive symptoms (PHQ-9), quality of life (WHO-QOL-BREF)mYes39 (25)9 (6)
    Carlbring et al, 2013 [19]SwedenAdults with MDD diagnosis (MADRS 15-30)n80 (82.5)44.4 (13.5)Browser-based digital BA intervention (Depressionshjälpen), minimal modules of ACToWLCp83qDepressive symptoms (BDI-II),r anxiety (BAI),s quality of life (QOLI)tYes0 (0)2 (5)
    Dahne et al, 2019 (Moodivate) [20]United StatesAdults with depressive symptoms (PHQ-8u ≥ 10)52 (84.6)43.79 (13.27)Smartphone-based BA app (Moodivate)CBTv and TAU8NoneDepressive symptoms (BDI-II)No5 (21)5 (26); 1 (11)
    Dahne et al, 2019 (Aptívate) [29]United StatesAdults with depressive symptoms (PHQ-8 ≥10)42 (66.7)36.05 (11.44)Smartphone-based BA app (Aptívate)CBT and TAU8NoneDepressive symptoms (BDI-II)No3 (14)1 (11); 5 (45)
    Jelinek et al, 2020 [21]GermanyAdults with depressive symptoms (PHQ-9 ≥4)104 (76.9)46.21 (10.24)Browser-based digital BA interventionMindfulness and TAU21Depressive symptoms (PHQ-9), quality of life (WHOQOL-BREF)No8 (22)5 (16); 3 (9)
    Lambert et al, 2018 [30]United KingdomAdults with depressive symptoms (PHQ-8 ≥ 10)62 (84)38.1 (12.3)Browser-based digital BA intervention (eMotion)WLC8NoneDepressive symptoms (PHQ-8)No7 (22)5 (17)
    Ly et al, 2014 [31]SwedenAdults with MDD diagnosis (PHQ-9 ≥5)81 (70)36.1 (10.8)Smartphone-based BA appMindfulness86Depressive symptoms (PHQ-9), anxiety (BAI), quality of life (QOLI)Yes4 (10)5 (12)
    Nyström et al, 2017 [32]SwedenAdults with MDD diagnosis (MADRS 15-35)286 (76)42.0 (13.5)Browser-based digital BA intervention (Lewinsohn), browser-based digital BA intervention (Martell)wPhysical activity without rational, physical activity with rational, WLC12NoneDepressive symptoms (PHQ-9), anxiety (GAD-7)xYes4 (6)9 (18); 12 (20); 7 (11); 5 (09)
    O\'Mahen et al, 2013 [34]United KingdomWomen with depressive symptoms (EPDS>12)y910 (100)32.2 (5.2)Browser-based digital BA intervention (postnatal iBA)TAU15NoneDepressive symptoms (EPDS)Yes281 (60.8)286 (63.9)
    O\'Mahen et al, 2014 [33]United KingdomWomen with MDD diagnosis (EPDS > 12)83 (100)NAzBrowser-based digital BA intervention (NetmumsHWD)TAU1710Depressive symptoms (EPDS), anxiety (GAD-7)No3 (3.6)8 (9.6)
    Stiles-Shields et al, 2019 [35]United StatesAdults with depressive symptoms (PHQ-9 ≥ 10)30 (76)37.6 (13.2)Smartphone-based BA app (Boost Me)CTaa and WLC62.5Depressive symptoms (PHQ-9)Yes0 (0)3 (10); 0 (0)

    aITT: intention-to-treat.

    bMeans and SDs are for complete baseline N available.

    cIG: intervention group.

    dCG: control group.

    ePHQ-9: Patient Health Questionnaire-9.

    fMeans and SDs for complete participant population were calculated from group-based means and SDs.

    gBA: behavioral activation.

    hEQ-5D-3L: Three-Level Version of EuroQol Five-Dimensional Questionnaire.

    iBADS-SF: Behavioral Activation for Depression Scale – Short Form.

    jMDD: major depressive disorder.

    kPDD: persistent depressive disorder.

    lTAU: treatment as usual.

    mWHO-QOL-BREF: WHO-Quality of Live Questionnaire.

    nMADRS: Montgomery-Åsberg Depression Rating Scale.

    oACT: acceptance and commitment therapy.

    pWLC: waitlist control group.

    qOnly the intervention group completed the follow-up.

    rBDI-II: Beck Depression Inventory.

    sBAI: Beck Anxiety Inventory.

    tQOLI: Quality of Life Inventory.

    uPHQ-8: Patient Health Questionnaire-8.

    vCBT: cognitive behavioral therapy.

    wIncluded in main analysis.

    xGAD-7: Generalized Anxiety Disorder 7-item Scale.

    yEPDS: Edinburgh Postnatal Depression Scale.

    zNA: not available.

    aaCT: cognitive therapy.

    Risk of Bias

    A visual summary of the risk of bias assessment is displayed in Figure 2. A detailed description of the authors’ judgments can be found in Multimedia Appendix 9. Due to assessment through self-report measures that made blinding impossible, all studies were classified as “with some concerns” (RoB: measurement of the outcome). Some concerns were further raised, if studies could not rule out nonadherence or unequal therapist support (deviations from the intended intervention) [20,29,30,32,35], did not present a preregistration or protocol (selection of the reported result) [19,31,33-35], or could not verify that dropout was not related to participants’ health status (missing outcome data) [21,30,31,33]. A high risk of bias occurred only for 1 study that had a very high dropout rate [34].

    ‎
    Figure 2. Risk of bias summary.

    Meta-Analyses of the Main Outcome of Depressive Symptoms

    Out of the 13 studies included, 12 reported effects of iBA compared to inactive CGs on depressive symptoms and were included in the main analysis [18-22,29,30,32-35]. A statistically significant effect was revealed favoring iBA against inactive CGs for the treatment of depressive symptoms, with an SMD of −0.49 (95% CI −0.63 to −0.34; P<.001) (Figure 3). The overall level of heterogeneity was moderate to substantial (I2=53%). Visual inspection of the funnel plot revealed slight asymmetry at the bottom right, suggesting some publication bias (Multimedia Appendix 10). None of the conducted sensitivity analyses changed the significance of the effect, as the effect size ranged from −0.37 to −0.55 in favor of iBA. Pure iBA interventions showed a slightly smaller effect [18,20-22,29,32,35]. At the 6-month follow-up, there was no significant effect (SMD −0.12; 95% CI −0.27 to 0.04; P=.13; Multimedia Appendix 11).

    In addition to the main analysis, meta-analyses of iBA compared to cognitive interventions [20,29,35] and iBA compared to mindfulness [21,31] were calculated. There was no significant effect in either of the 2 comparisons (cognitive interventions: SMD 0.14, 95% CI −0.36 to 0.63, P=.59; I2=9%; mindfulness: SMD −0.27, 95% CI −0.62 to 0.07, P=.12, I2=0%; Figure 3), and heterogeneity was low in both cases.

    ‎
    Figure 3. Effects of iBA in comparison to (A) inactive CGs on depression, (B) cognitive intervention on depression, and (C) mindfulness on depression. CG: control group; iBA: internet-based behavioral activation.

    Subgroup Analyses

    Subgroup analyses (Figure 4) and sensitivity analyses (Multimedia Appendix 12) were only performed for the main analysis (depressive symptoms). Studies on browser-based digital interventions [18,19,21,30,32-34] showed slightly higher effects (SMD −0.54; 95% CI −0.72 to −0.36; P<.001; I2=41%) than studies on a smartphone app (SMD −0.39; 95% CI −0.62 to −0.17; P<.001; I2=48%) [20,22,29,35]. The subgroup analysis on the level of guidance revealed significant results only for interventions with minimal guidance (SMD −0.50 95% CI −0.77 to −0.22; P<.001) [19,22,30] and guided interventions (SMD −0.50 95% CI −0.64 to −0.37; P<.001) [18,32-35], whereas the effect of unguided interventions [20,21,29] did not reach significance. Heterogeneity for interventions with minimal guidance was substantial (I2=75%) and low (I2=0%) for guided interventions.

    ‎
    Figure 4. Effects of iBA on depression. Subgroup analyses for (A) mode of delivery and (B) guidance. CG: control group; iBA: internet-based behavioral activation.

    Meta-Analyses of Secondary Outcomes

    Secondary outcome analyses were conducted for anxiety, quality of life, and activation (Multimedia Appendix 13).

    In total, 4 studies reported results for the secondary outcome of anxiety symptoms [19,30,32,33]. The meta-analysis on anxiety symptoms showed a statistically significant effect in favor of iBA compared to inactive CGs for the treatment of anxiety (SMD −0.59; 95% CI −0.83 to −0.35; P<.001) with low statistical heterogeneity (I2=0%).

    Quality of life was reported by 5 studies [18,19,21,22]. A statistically significant effect was found beneficial to iBA compared to inactive CGs (SMD 0.20; 95% CI 0.10-0.29; P<.001), with higher scores indicating higher quality of life. Statistical heterogeneity was low (I2=0%).

    The outcome of activation data from 3 studies could be combined [21,22], which used the Behavioral Activation for Depression Scale [36]. A statistically significant effect favoring iBA compared to inactive CGs was found (SMD 0.25; 95% CI 0.01-0.48; P<.05) for activation with higher scores, indicating higher activation. Heterogeneity for this comparison was substantial (I2=66%).


    Summary of Findings

    The present review and meta-analysis summarizes the current state of research in the dynamic field of iBA. Across 12 RCTs, iBA appeared to be more effective than inactive CGs with medium effect sizes. This effect was robust in all conducted sensitivity analyses. Subgroup analyses revealed slightly higher effect sizes for browser-based digital interventions than smartphone apps [37]. Interventions with guidance demonstrated their effectiveness, whereas interventions without guidance did not. Our meta-analysis showed no differences in effectiveness between minimal guidance and more intensive forms of guidance. The investigation of the optimal type and amount of guidance is a pending topic that could make a critical difference concerning the cost-effectiveness and scalability of interventions [38]. The stability of effects could not be found at the 6-month follow-up. Yet, only a very limited number of follow-up data was available. Future research should clarify the long-term effects of iBA.

    Regarding our data, the effects of iBA on depressive symptoms seem to be comparable to the effects of internet-based CBT or mindfulness interventions. This finding equals the results of other meta-analyses reporting comparable effect sizes for different treatment approaches [9,10]. BA is associated with several key strengths such as low-cost applicability by nurses and lay counselors [39,40]. It could bridge waiting times and serve as a low-threshold access to psychotherapy.

    In our meta-analyses, iBA is also associated with reduced anxiety symptoms and increased quality of life and activation. The effects on anxiety symptoms underline the transdiagnostic potential of BA [41,42]. There is initial evidence that BA is effective in psychotic disorders (reduction of negative symptoms) [43], eating disorders [44], and posttraumatic stress disorders [45].

    There was clinical heterogeneity of included interventions regarding settings [29,30], populations [33,34], duration of the interventions [21,33], the number of modules [22,35], and cultural groups [18,22], which suggests a broad field of iBA applications. The mode of intervention delivery of included studies, however, was limited to browser-based interventions and smartphone apps. For this review, we did not identify any iBA interventions involving chatbots, artificial intelligence systems, or just-in-time adaptive interventions. Statistical heterogeneity was moderate to substantial for the main analysis and low to substantial for the secondary outcomes meta-analyses.

    Strengths and Limitations

    We have conducted a comprehensive review and meta-analysis in accordance with PRISMA guidelines, including independent ratings, sensitivity analyses, and the assessment of publication bias. An elaborated search term based on former meta-analyses allowed us to conduct a specific search on iBA. The specificity of our search may have led to the nondetection of a few particular studies that did not label their BA interventions as “behavioral activation” or the synonyms we searched for. Yet, the fact that we detected all studies of our validation set supports our approach. We did not search for unpublished research and only included papers in English or German. We were able to sharpen the focus on iBA, excluding interventions that were not predominantly transmitted in a web-based setting (eg, blended care) and that contained other main elements besides BA. The risk of bias rating revealed some concerns for all studies, and there was evidence of possible publication bias. The main concern was missing external assessment of depressive symptomatology, as all included studies in this meta-analysis relied on self-report measures. Interventions varied in their intensity, and many studies lacked a detailed intervention description. For the main analysis, we observed a moderate to substantial statistical heterogeneity. By separating interventions based on their level of guidance, heterogeneity was lower in both subgroups. To reduce heterogeneity in future meta-analyses, it might therefore be useful to consider conducting separate analyses, depending on the level of guidance. The different lengths of interventions also resulted in different postmeasurement time points and may have also contributed to heterogeneity. If in the future more primary studies with different postmeasurement time points are available, these should be grouped to inform about the stability of the effect over time.

    Conclusions

    The findings of this study suggest that iBA is effective in reducing depressive symptoms and increasing activation in daily life. It may also reduce anxiety symptoms of individuals with depression and improve their quality of life. There is an enormous potential for iBA interventions in lower-income countries and health care systems with limited therapeutic capacities.

    Acknowledgments

    This review and meta-analysis was made possible by funding from the German Research Foundation (Deutsche Forschungsgemeinschaft, grant number 425987318) and by an institutional budget of the University of Freiburg, Institute of Psychology. The article processing charge was funded by the Open Access Publication Fund of the University of Freiburg.

    Authors' Contributions

    CSA, LVK, and CM-W contributed to the concept and design of the study. CSA, CM-W, and SMR were responsible for data acquisition, analysis, and interpretation. CSA is responsible for the statistical analysis and has full access to all the data in the study. CSA, CM-W, and LVK drafted the manuscript. All authors contributed to the critical revision of the manuscript and approved its final version. CM-W and LVK supervised the study.

    Conflicts of Interest

    None declared.

    ‎
    Multimedia Appendix 1

    PRISMA checklist.

    PDF File (Adobe PDF File), 188 KB
    ‎
    Multimedia Appendix 2

    Amendments and specifications to the PROSPERO registration.

    PDF File (Adobe PDF File), 103 KB
    ‎
    Multimedia Appendix 3

    Search strategies.

    PDF File (Adobe PDF File), 71 KB
    ‎
    Multimedia Appendix 4

    Validation set.

    PDF File (Adobe PDF File), 105 KB
    ‎
    Multimedia Appendix 5

    Inclusion criteria checklist.

    PDF File (Adobe PDF File), 159 KB
    ‎
    Multimedia Appendix 6

    List of extracted data.

    PDF File (Adobe PDF File), 136 KB
    ‎
    Multimedia Appendix 7

    Levels of guidance.

    PDF File (Adobe PDF File), 89 KB
    ‎
    Multimedia Appendix 8

    Detailed intervention description of included studies.

    PDF File (Adobe PDF File), 202 KB
    ‎
    Multimedia Appendix 9

    Risk of bias assessment. Authors' judgements.

    PDF File (Adobe PDF File), 229 KB
    ‎
    Multimedia Appendix 10

    Funnel plot.

    PDF File (Adobe PDF File), 123 KB
    ‎
    Multimedia Appendix 11

    Forest plot of 6-month follow-up.

    PDF File (Adobe PDF File), 210 KB
    ‎
    Multimedia Appendix 12

    Forest plot of sensitivity analyses.

    PDF File (Adobe PDF File), 700 KB
    ‎
    Multimedia Appendix 13

    Forest plots of secondary outcomes anxiety, quality of life, and activation.

    PDF File (Adobe PDF File), 398 KB
    1. Depression and other common mental disorders: global health estimates. World Health Organization. Geneva, Switzerland: WHO Document Production Services; 2017.   URL: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER -2017.2-eng.pdf [accessed 2023-04-18]
    2. Gilman SE, Sucha E, Kingsbury M, Horton NJ, Murphy JM, Colman I. Depression and mortality in a longitudinal study: 1952-2011. CMAJ 2017 Oct 23;189(42):E1304-E1310 [FREE Full text] [CrossRef] [Medline]
    3. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 2015 Apr;72(4):334-341 [FREE Full text] [CrossRef] [Medline]
    4. Herrman H, Kieling C, McGorry P, Horton R, Sargent J, Patel V. Reducing the global burden of depression: a Lancet-world psychiatric association commission. Lancet 2019 Jun 15;393(10189):e42-e43 [FREE Full text] [CrossRef] [Medline]
    5. Thornicroft G, Chatterji S, Evans-Lacko S, Gruber M, Sampson N, Aguilar-Gaxiola S, et al. Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry 2017 Feb;210(2):119-124 [FREE Full text] [CrossRef] [Medline]
    6. Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, et al. Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet 2016 Aug 27;388(10047):871-880 [FREE Full text] [CrossRef] [Medline]
    7. Lewinsohn PM. A behavioral approach to depression. In: Friedman RJ, Katz MM, editors. The Psychology of Depression: Contemporary Theory and Research. London: John Wiley & Sons; 1974.
    8. Kanter JW, Manos RC, Bowe WM, Baruch DE, Busch AM, Rusch LC. What is behavioral activation? A review of the empirical literature. Clin Psychol Rev 2010 Aug;30(6):608-620 [FREE Full text] [CrossRef] [Medline]
    9. Uphoff E, Ekers D, Robertson L, Dawson S, Sanger E, South E, et al. Behavioural activation therapy for depression in adults. Cochrane Database Syst Rev 2020 Jul 06;7(7):CD013305 [FREE Full text] [CrossRef] [Medline]
    10. Cuijpers P, Karyotaki E, de Wit L, Ebert DD. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. Psychother Res 2020 Mar;30(3):279-293 [FREE Full text] [CrossRef] [Medline]
    11. Stein AT, Carl E, Cuijpers P, Karyotaki E, Smits JAJ. Looking beyond depression: a meta-analysis of the effect of behavioral activation on depression, anxiety, and activation. Psychol Med 2021 Jul;51(9):1491-1504 [FREE Full text] [CrossRef] [Medline]
    12. Wilson PH, Goldin JC, Charbonneau-Powis M. Comparative efficacy of behavioral and cognitive treatments of depression. Cogn Ther Res 1983 Apr;7(2):111-124 [FREE Full text] [CrossRef]
    13. Ekers D, Richards D, McMillan D, Bland JM, Gilbody S. Behavioural activation delivered by the non-specialist: phase II randomised controlled trial. Br J Psychiatry 2011 Jan;198(1):66-72 [FREE Full text] [CrossRef] [Medline]
    14. Barth J, Munder T, Gerger H, Nüesch E, Trelle S, Znoj H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med 2013;10(5):e1001454 [FREE Full text] [CrossRef] [Medline]
    15. Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, et al. A component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol 1996 Apr;64(2):295-304 [FREE Full text] [CrossRef] [Medline]
    16. Lejuez CW, Hopko DR, Hopko SD. A brief behavioral activation treatment for depression. Treatment manual. Behav Modif 2001 Apr;25(2):255-286 [FREE Full text] [CrossRef] [Medline]
    17. Huguet A, Miller A, Kisely S, Rao S, Saadat N, McGrath PJ. A systematic review and meta-analysis on the efficacy of internet-delivered behavioral activation. J Affect Disord 2018 Aug 01;235:27-38 [FREE Full text] [CrossRef] [Medline]
    18. Arjadi R, Nauta MH, Scholte WF, Hollon SD, Chowdhary N, Suryani AO, et al. Internet-based behavioural activation with lay counsellor support versus online minimal psychoeducation without support for treatment of depression: a randomised controlled trial in Indonesia. Lancet Psychiatry 2018 Sep;5(9):707-716 [FREE Full text] [CrossRef] [Medline]
    19. Carlbring P, Hägglund M, Luthström A, Dahlin M, Kadowaki Å, Vernmark K, et al. Internet-based behavioral activation and acceptance-based treatment for depression: a randomized controlled trial. J Affect Disord 2013 Jun;148(2-3):331-337 [FREE Full text] [CrossRef] [Medline]
    20. Dahne J, Lejuez CW, Diaz VA, Player MS, Kustanowitz J, Felton JW, et al. Pilot randomized trial of a self-help behavioral activation mobile app for utilization in primary care. Behav Ther 2019 Jul;50(4):817-827 [FREE Full text] [CrossRef] [Medline]
    21. Jelinek L, Arlt S, Moritz S, Schröder J, Westermann S, Cludius B. Brief web-based intervention for depression: randomized controlled trial on behavioral activation. J Med Internet Res 2020 Mar 26;22(3):e15312 [FREE Full text] [CrossRef] [Medline]
    22. Araya R, Menezes PR, Claro HG, Brandt LR, Daley KL, Quayle J, et al. Effect of a digital intervention on depressive symptoms in patients with comorbid hypertension or diabetes in Brazil and Peru: two randomized clinical trials. JAMA 2021;325(18):1852-1862 [FREE Full text] [CrossRef] [Medline]
    23. Spates CR, Padalino R, Hale AC, Germain CS, Nimmo K, Kohler R. A review of web‐based technology in behavioural activation. Clin Psychol 2016;20(1):27-35 [FREE Full text] [CrossRef]
    24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009 Aug 18;151(4):W65-W94 [FREE Full text] [CrossRef] [Medline]
    25. Josephine K, Josefine L, Philipp D, David E, Harald B. Internet- and mobile-based depression interventions for people with diagnosed depression: a systematic review and meta-analysis. J Affect Disord 2017 Dec 01;223:28-40 [FREE Full text] [CrossRef] [Medline]
    26. The Cochrane Collaboration. Review Manager 5.4 (RevMan 5.4). 2020.   URL: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman [accessed 2022-03-13]
    27. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. GRADE Handbook.: GRADE Working Group; 2013.   URL: https://gdt.gradepro.org/app/handbook/handbook.html [accessed 2022-02-21]
    28. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019 Aug 28;366:l4898 [FREE Full text] [CrossRef] [Medline]
    29. Dahne J, Collado A, Lejuez CW, Risco CM, Diaz VA, Coles L, et al. Pilot randomized controlled trial of a Spanish-language behavioral activation mobile app (¡Aptívate!) for the treatment of depressive symptoms among united States latinx adults with limited English proficiency. J Affect Disord 2019 May 01;250:210-217 [FREE Full text] [CrossRef] [Medline]
    30. Lambert JD, Greaves CJ, Farrand P, Price L, Haase AM, Taylor AH. Web-based intervention using behavioral activation and physical activity for adults with depression (the eMotion study): pilot randomized controlled trial. J Med Internet Res 2018;20(7):e10112 [FREE Full text] [CrossRef] [Medline]
    31. Ly KH, Trüschel A, Jarl L, Magnusson S, Windahl T, Johansson R, et al. Behavioural activation versus mindfulness-based guided self-help treatment administered through a smartphone application: a randomised controlled trial. BMJ Open 2014 Jan 09;4(1):e003440 [FREE Full text] [CrossRef] [Medline]
    32. Nyström MBT, Stenling A, Sjöström E, Neely G, Lindner P, Hassmén P, et al. Behavioral activation versus physical activity via the internet: a randomized controlled trial. J Affect Disord 2017 Jun;215:85-93 [FREE Full text] [CrossRef] [Medline]
    33. O'Mahen HA, Richards DA, Woodford J, Wilkinson E, McGinley J, Taylor RS, et al. Netmums: a phase II randomized controlled trial of a guided internet behavioural activation treatment for postpartum depression. Psychol Med 2014 Jun;44(8):1675-1689 [FREE Full text] [CrossRef] [Medline]
    34. O'Mahen HA, Woodford J, McGinley J, Warren FC, Richards DA, Lynch TR, et al. Internet-based behavioral activation--treatment for postnatal depression (Netmums): a randomized controlled trial. J Affect Disord 2013 Sep 25;150(3):814-822 [FREE Full text] [CrossRef] [Medline]
    35. Stiles-Shields C, Montague E, Kwasny MJ, Mohr DC. Behavioral and cognitive intervention strategies delivered via coached apps for depression: pilot trial. Psychol Serv 2019 May;16(2):233-238 [FREE Full text] [CrossRef] [Medline]
    36. Kanter JW, Mulick PS, Busch AM, Berlin KS, Martell CR. The behavioral activation for depression scale (BADS): psychometric properties and factor structure. J Psychopathol Behav Assess 2007;29(3):191-202 [FREE Full text] [CrossRef]
    37. Moshe I, Terhorst Y, Philippi P, Domhardt M, Cuijpers P, Cristea I, et al. Digital interventions for the treatment of depression: a meta-analytic review. Psychol Bull 2021 Aug;147(8):749-786 [FREE Full text] [CrossRef] [Medline]
    38. Karyotaki E, Efthimiou O, Miguel C, Bermpohl FMG, Furukawa TA, Cuijpers P, Individual Patient Data Meta-Analyses for Depression (IPDMA-DE) Collaboration. Internet-based cognitive behavioral therapy for depression: a systematic review and individual patient data network meta-analysis. JAMA Psychiatry 2021 Apr 01;78(4):361-371 [FREE Full text] [CrossRef] [Medline]
    39. Ekers DM, Dawson MS, Bailey E. Dissemination of behavioural activation for depression to mental health nurses: training evaluation and benchmarked clinical outcomes. J Psychiatr Ment Health Nurs 2013 Mar;20(2):186-192 [FREE Full text] [CrossRef] [Medline]
    40. Patel V, Weobong B, Weiss HA, Anand A, Bhat B, Katti B, et al. The healthy activity program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial. Lancet 2017 Jan 14;389(10065):176-185 [FREE Full text] [CrossRef] [Medline]
    41. Chen J, Liu X, Rapee RM, Pillay P. Behavioural activation: a pilot trial of transdiagnostic treatment for excessive worry. Behav Res Ther 2013 Sep;51(9):533-539 [FREE Full text] [CrossRef] [Medline]
    42. Fernández-Rodríguez C, Coto-Lesmes R, Martínez-Loredo V, González-Fernández S, Cuesta M. Is activation the active ingredient of transdiagnostic therapies? A randomized clinical trial of behavioral activation, acceptance and commitment therapy, and transdiagnostic cognitive-behavioral therapy for emotional disorders. Behav Modif 2023 Jan;47(1):3-45 [FREE Full text] [CrossRef] [Medline]
    43. Mairs H, Lovell K, Campbell M, Keeley P. Development and pilot investigation of behavioral activation for negative symptoms. Behav Modif 2011 Sep;35(5):486-506 [FREE Full text] [CrossRef] [Medline]
    44. Alfonsson S, Parling T, Ghaderi A. Group behavioral activation for patients with severe obesity and binge eating disorder: a randomized controlled trial. Behav Modif 2015 Mar;39(2):270-294 [FREE Full text] [CrossRef] [Medline]
    45. Etherton JL, Farley R. Behavioral activation for PTSD: a meta-analysis. Psychol Trauma 2022 Jul;14(5):894-901 [FREE Full text] [CrossRef] [Medline]

    ‎
    BA: behavioral activation
    CBT: cognitive behavioral therapy
    CG: control group
    iBA: internet-based behavioral activation
    ITT: intention-to-treat
    PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
    RCT: randomized controlled trial
    RoB 2: Cochrane Collaboration’s Risk of Bias tool 2
    SMD: standardized mean difference

    Edited by T Leung; submitted 04.08.22; peer-reviewed by J Etherton, A Salamanca-Sanabria, L Hess; comments to author 09.11.22; revised version received 21.12.22; accepted 15.03.23; published 11.05.23

    Copyright

    ©Carolin Sophie Alber, Lena Violetta Krämer, Sophia Marie Rosar, Claudia Mueller-Weinitschke. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 25.05.2023.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.